IBRX$3.465
Chart
Performance
Key Stats
AI IBRX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldImmunityBio shows potential in its sector but faces significant headwinds. While there are some positive fundamental and technical indicators, the overall financial health and profitability are concerns that warrant a cautious approach.
Thematic
ImmunityBio operates in the biotechnology sector, focusing on immuno-oncology and infectious diseases. The company's primary product, Anktiva, targets a specific form of bladder cancer. The overall thematic appeal is moderate, with potential growth drivers in its therapeutic focus but also facing competitive pressures and regulatory hurdles.
Fundamental
ImmunityBio's financial fundamentals are currently weak, characterized by significant losses, negative earnings, and substantial debt. While revenue is growing, it remains low relative to expenses and market capitalization, leading to a low fundamental score.
Technical
The stock price is trading below key moving averages and shows mixed signals from oscillators. While there are some short-term positive movements, the overall trend appears bearish, suggesting caution.
| Factor | Score |
|---|---|
| Biotechnology & Pharmaceuticals | 60 |
| Oncology Treatments | 70 |
| Infectious Diseases | 50 |
| Regulatory Environment | 70 |
| Research & Development Pipeline | 50 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 75 |
| Balance Sheet Health | 20 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive Short-Term Performance
The stock has seen a 1.27% increase in its current price, reaching $2.785. Its 5-day performance is -3.97%, 1-month performance is -2.96%, and Year-to-Date performance is 8.37%.
Mixed but Potential Upward Momentum
Some technical indicators across various timeframes suggest potential buying opportunities. For instance, the 1-minute Stochastic %K is at 11.08 (Buy), Commodity Channel Index is -105.05 (Buy), and Stochastic RSI Fast is 4.14 (Buy). The 1-day 100-day and 200-day moving averages are showing 'Buy' signals.
Bearish Points (7)
Extremely High Valuation Multiples
The Price-to-Sales (P/S) ratios are exceptionally high across all periods (TTM: 81.5, 2024: 153.2, 2023: 3951.9), suggesting the company is valued significantly higher than its current revenue.
Consistent Net Losses
The company has consistently reported net losses, with a TTM net income of -$274.537 million. The net margin is negative across all reported periods, with a TTM net margin of -2804.8%.
Calendar
August 2025
11
Next Earnings Date
H: $-0.09
A: $-0.10
L: $-0.12
H: 24.50M
A: 21.95M
L: 20.00M
Profile
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Seasonals
Price Target
11.40 USD
The 39 analysts offering 1 year price forecasts for IBRX have a max estimate of 30.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Part of the broader 'Nant' ecosystem founded by Dr. Patrick Soon-Shiong, who also founded ImmunityBio. NANT often collaborates with IBRX on precision medicine and data integration for cancer therapies, making it a very close related entity.
Weight: 90
Direct competitor and peer in the allogeneic (off-the-shelf) natural killer (NK) cell therapy space, which is a core focus area for ImmunityBio.
Weight: 88
Leading company in iPSC-derived NK and T cell therapies, representing a direct competitor and comparable in the broader allogeneic cell therapy and immuno-oncology landscape.
Weight: 85
Focuses on developing innate cell engagers, particularly for NK cells, making it a close competitor and peer to ImmunityBio in leveraging NK cell activity for cancer treatment.